Table 1.
The baseline clinicopathological characteristics of the included patients.
| Variables | Training group (n = 57) |
Validation group (n = 25) |
||||
|---|---|---|---|---|---|---|
| MPRa
(n = 33) |
Non-MPR (n = 24) |
p-Value | MPR (n = 13) |
Non-MPR (n = 12) |
p-Value | |
| Age (%) | 1.00 | 0.57 | ||||
| ≤60 | 12 (36.4) | 9 (37.5) | 4 (30.8) | 6 (50.0) | ||
| >60 | 21 (63.6) | 15 (62.5) | 9 (69.2) | 6 (50.0) | ||
| Gender (%) | 0.57 | 1.00 | ||||
| Male | 29 (87.9) | 23 (95.8) | 12 (92.3) | 12 (100.0) | ||
| Female | 4 (12.1) | 1 (4.2) | 1 (7.7) | 0 (0.0) | ||
| BMIb (%) | 1.00 | 1.00 | ||||
| ≤24 | 8 (24.2) | 5 (20.8) | 3 (23.1) | 3 (25.0) | ||
| >24 | 25 (75.8) | 19 (79.2) | 10 (76.9) | 9 (75.0) | ||
| Tumor location (%) | 0.79 | 0.95 | ||||
| Upper thorax | 5 (15.2) | 5 (20.8) | 2 (15.4) | 2 (16.7) | ||
| Middle thorax | 16 (48.5) | 12 (50.0) | 4 (30.8) | 3 (25.0) | ||
| Lower thorax | 12 (36.4) | 7 (29.2) | 7 (53.8) | 7 (58.3) | ||
| cT stage (%) | 0.50 | 0.39 | ||||
| cT1 | 0 (0.0) | 1 (4.2) | 0 (0.0) | 1 (8.3) | ||
| cT2 | 9 (27.3) | 5 (20.8) | 3 (23.1) | 1 (8.3) | ||
| cT3 | 23 (69.7) | 16 (66.7) | 10 (76.9) | 9 (75.0) | ||
| cT4 | 1 (3.0) | 2 (8.3) | 0 (0.0) | 1 (8.3) | ||
| cN stage (%) | <0.01 | 0.62 | ||||
| cN0 | 3 (9.1) | 12 (50.0) | 3 (23.1) | 2 (16.7) | ||
| cN1 | 12 (36.4) | 6 (25.0) | 4 (30.8) | 6 (50.0) | ||
| cN2 | 15 (45.5) | 6 (25.0) | 6 (46.2) | 4 (33.3) | ||
| cN3 | 3 (9.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Clinical stage (%) | 0.07 | 0.50 | ||||
| I | 0 (0.0) | 1 (4.2) | 0 (0.0) | 1 (8.3) | ||
| II | 6 (18.2) | 11 (45.8) | 4 (30.8) | 3 (25.0) | ||
| III | 23 (69.7) | 10 (41.7) | 9 (69.2) | 7 (58.3) | ||
| IV | 4 (12.1) | 2 (8.3) | 0 (0.0) | 1 (8.3) | ||
| Pathological differentiation (%) | 0.06 | 0.05 | ||||
| Moderately | 9 (27.3) | 13 (54.2) | 2 (15.4) | 5 (41.7) | ||
| Poorly | 12 (36.4) | 8 (33.3) | 4 (30.8) | 6 (50.0) | ||
| Unknown | 12 (36.4) | 3 (12.5) | 7 (53.8) | 1 (8.3) | ||
| Immunotherapy (%) | 0.07 | 0.23 | ||||
| Pembrolizumab | 5 (15.2) | 4 (16.7) | 2 (15.4) | 1 (8.3) | ||
| Sintilimab | 6 (18.2) | 6 (25.0) | 3 (23.1) | 3 (25.0) | ||
| Camrelizumab | 1 (3.0) | 4 (16.7) | 0 (0.0) | 3 (25.0) | ||
| Toripalimab | 0 (0.0) | 2 (8.3) | 0 (0.0) | 1 (8.3) | ||
| Tislelizumab | 21 (63.6) | 8 (33.3) | 8 (61.5) | 4 (33.3) | ||
| Treatment cycles (%) | 1.00 | 0.44 | ||||
| 2 cycles | 29 (87.9) | 21 (87.5) | 8 (61.5) | 10 (83.3) | ||
| >2 cycles | 4 (12.1) | 3 (12.5) | 5 (38.5) | 2 (16.7) | ||
| Radiotherapy (%) | <0.01 | 0.17 | ||||
| Yes | 26 (78.8) | 6 (25.0) | 10 (76.9) | 5 (41.7) | ||
| No | 7 (21.2) | 18 (75.0) | 3 (23.1) | 7 (58.3) | ||
| Interval time* (%) | 0.18 | 0.31 | ||||
| ≤90 days | 6 (18.2) | 9 (37.5) | 2 (15.4) | 5 (41.7) | ||
| >90 days | 27 (81.8) | 15 (62.5) | 11 (84.6) | 7 (58.3) | ||
*Means the time from the day of the first neoadjuvant immunotherapy to the day of surgery. aMajor pathological response. bBody mass index.